

Clinical trials of desirudin

TrialResults-center www.trialresultscenter.org

1 thrombosis prevention

Trial	Treatments	Patients	Trials design and methods
desirudin vs enoxaparin			
Ericksson , 1997 n=NA follow-up:	desirudin 15mg SC twice daily for 8-12 days versus enoxaparin 40mg once daily for 8-12 days	Patients who undergo total hip replacement	Parallel groups double blind Europe
desirudin vs UFH			
REVASC , 1997 n=225/220 follow-up:	desirudin 15mg twice daily versus unfractionated heparin 5000 IU three times a day	patients having a primary elective total hip replacement	Parallel groups
Eriksson , 1996 n=1119 follow-up:	recombinant hirudin, desirudin (CGP 39393) 10, 15, or 20 mg twice daily started just before surgery and continued for 8-11 days versus unfractionated heparin 5000 IU three times daily started just before surgery and continued for 8-11 days	patients undergoing elective hip surgery	Parallel groups double blind Europe

More details and results :

- antithrombotics for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q37>
- antithrombotics for thrombosis prevention in elective hip replacement at <http://www.trialresultscenter.org/go-Q39>

References

Ericksson, 1997:

Eriksson BI, Wille-Jrgensen P, Klebo P, Mouret P, Rosencher N, Bsck P, Baur M, Ekman S, Bach D, Lindbratt S, Close P A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-35 [9358126]

REVASC, 1997:

Eriksson BI, Ekman S, Lindbratt S, Baur M, Bach D, Torholm C, Klebo P, Close P Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. *J Bone Joint Surg Am* 1997;79:326-33 [[9070519](#)]

Eriksson, 1996:

Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. *Lancet* 1996;347:635-9 [[8596376](#)]

Entry terms: candesartan, candesartan cilexetil, TCV 116, TCV-116, Atacand, Blopress, Kenzen, Amias, Parapres, candesartan, CV 11974, CV11974, CV-11974,